SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Elie M, Cole MG, Primeau FJ, Bellavance F. Delirium risk factors in elderly hospitalized patients. J. Gen. Intern. Med. 1998; 13: 204212.DOI: 10.1046/j.1525-1497.1998.00047.x
  • 2
    Levkoff S, Cleary P, Liptzin B, Evans DA. Epidemiology of delirium: An overview of research issues and findings. Int. Psychogeriatr. 1991; 3: 149167.
  • 3
    Massie MJ, Holland JC, Glass E. Delirium in terminally ill cancer patients. Am. J. Psychiatry 1983; 140: 10481050.
  • 4
    Someya T, Endo T, Hara T, Yagi G, Suzuki J. A survey on the drug therapy of delirium. Psychiatry Clin. Neurosci. 2001; 55: 397401.DOI: 10.1046/j.1440-1819.2001.00881.x
  • 5
    Shapiro BA, Warren J, Egol AB et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: An executive summary. Crit. Care Med. 1995; 23: 15961600.
  • 6
    Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I. Pharmacology, pharmacokinetics and efficacy. Ann. Pharmacother. 1999; 33: 7385.
  • 7
    Casey DE. Side effects profiles of new antisychotic agents. J. Clin. Psychiatry 1996; 57 (Suppl. 11): 4045.
  • 8
    Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: Part II. Adverse effects, drug interactions, and costs. Ann. Pharmacother. 1999; 33: 210 217.
  • 9
    Sipahimalani A & Masand PS. Use of risperidone in delirium: Case reports. Ann. Clin. Psychiatry 1997; 9: 105107.
  • 10
    Sipahimalani A & Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 1998; 39: 422430.
  • 11
    Anand HS. Olanzapine in an intensive care unit. Can. J. Psychiatry 1999; 44: 397.
  • 12
    Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J. Clin. Psychiatry 1999; 60 (Suppl. 10): 5260.
  • 13
    Frank C. Delirium, consent to treatment, and Shakespeare: A geriatric experience. Can. Fam. Physician 1999; 45: 875876.
  • 14
    Solomons K & Geiger O. Olanzapine use in the elderly: A retrospective analysis. Can. J. Psychiatry 2000; 45: 151155.
  • 15
    Ravona-Springer R, Dolberg OT, Hirschmann S, Grunhaus L. Delirium in elderly patients treated with risperidone: A report of three cases. J. Clin. Psychopharmacol. 1998; 18: 171172.
  • 16
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Washington DC, 1994.
  • 17
    Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res. 1998; 23: 89 97.
  • 18
    Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch. Gen. Psychiatry 2000; 57: 841849.
  • 19
    Pi EH, Wang AL, Gray GE. Asian/non-Asian transcultural tricyclic antidepressant psychopharmacology: A review. Prog. Neuropsychopharmacol. Biol. Psychiatry 1993; 17: 691702.
  • 20
    Tueth MJ. Emergencies caused by side effects of psychiatric medications. Am. J. Emerg. Med. 1994; 12: 212216.
  • 21
    Tune LE & Egeli S. Acetylcholine and delirium. Dement. Geriatr. Cogn. Disord. 1999; 10: 342344.
  • 22
    Itil T & Fink M. Anticholinergic drug-induced delirium: Experimental modification, quantitative EEG and behavioral correlations. J. Nerv. Ment. Dis. 1996; 143: 492507.
  • 23
    Tune LE & Bylsma FW. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int. Psychogeriatr. 1991; 3: 397408.
  • 24
    Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol. 1996; 14: 8796.
  • 25
    Bymaster FP & Falcone JF. Decreased binding affinity of olanzapine and clozapine for clonal human muscarinic receptor subtypes in intact CHO cells in physiological medium. Eur. J. Pharmacol. 2000; 390: 245248.
  • 26
    Bymaster FP, Moore NA, Nakazawa T. Review of the preclinical pharmacology of olanzapine: A MARTA class antipsychotic. Jpn. J. Clin. Psychopharmacol. 1999; 2: 885911.
  • 27
    Bymaster FP, Nelson DL, DeLapp NW et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and -adrenergic receptors in vitro. Schizophr. Res. 1999; 37: 107122.
  • 28
    Street JS, Clark WS, Gannon KS et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry 2000; 57: 968976.